Lilly Is Prepared For Potential Prasugrel Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has not yet notified the company of an upcoming advisory panel meeting, executives say.
You may also be interested in...
Lilly Prasugrel Delay Could Extend Well Into 2009
FDA is looking at a February advisory committee for Lilly/Daiichi anti-clotting drug. Safety issues are one potential topic.
US Medicare Plans 'Can' Cover Wegovy, CMS Says, But Will They?
Medicare is making clear that Part D ‘can’ cover GLP-1 inhibitors that are approved for cardiovascular indications – but in language that seems to leave plans considerable discretion for now. The formulary review process for 2025 may be a more important milestone for changes.
An Artificial Intelligence Milestone For US FDA
A project to validate a depression severity measurement tool that employs artificial intelligence for use in drug trials is moving forward at FDA. The milestone is a sign of things to come – and of the incremental process for AI adoption by the regulator.